BIIB Jun 2024 240.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 03:56PM EDT. Market open.
| Previous close | 0.7500 |
| Open | 0.7300 |
| Bid | 1.1000 |
| Ask | 2.0000 |
| Strike | 240.00 |
| Expiry date | 2024-06-21 |
| Day's range | 0.7300 - 1.2500 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.24k |
GlobeNewswireBiogen Receives European Commission Approval for QALSODY® (tofersen), the First Therapy to Treat a Rare, Genetic Form of ALS
SOD1-ALS is a devastating, uniformly fatal, and ultra-rare genetic form of ALS estimated to affect less than 1,000 people in Europe1QALSODY is Biogen’s third rare disease therapy to be approved in the EU, demonstrating the company’s commitment to addressing diseases with a high unmet needWith QALSODY, Biogen has helped advance neurofilament as a tool to optimize clinical trial design in ALS, offering the potential to expedite further breakthroughs in the field CAMBRIDGE, Mass., May 30, 2024 (GLO
Investor's Business DailyIs Eli Lilly Stock A Buy On A Recent Crohn's Disease-Related Rally?
Eli Lilly stock broke out after the company reported positive results for Crohn's disease drug. Is LLY stock a buy right now?
ZacksQiagen (QGEN) Up 1.6% Since Last Earnings Report: Can It Continue?
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
© 2024 Yahoo. All rights reserved.